Vyriad Inc
Vyriad, Inc. is a clinical-stage biotechnology company developing targeted genetic medicines for cancer and other serious diseases. The company leverages engineered viruses, viral vectors, and viral envelope glycoproteins to deliver therapeutic genes directly to selected cells, advancing programs in oncolytic virotherapy, in vivo gene therapy, and gene-editing with partnerships including Regeneron and Novartis.
Leadership & Board
- Current Number of Employees
- 59
- Current LinkedIn Followers
- 5,416
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $85M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $85M
- Latest Funding Round
- Series B
- Post-Money Valuation
- ―
Employee Trend
Vyriad Inc had 59 employees as of October 12, 2026. The number of employees increased by 2 (3.51%) week-over-week.
Social Trend
Vyriad Inc had 5,416 followers as of October 12, 2026. The number of followers increased by 33 (0.61%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Dec 23, 2025 | Series B | $85.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Harry Stine | Series B |
| Multiple family offices | Series B |
Similar Companies
A snapshot of private companies similar to Vyriad Inc, helping you discover and navigate related company profiles.
Related News and Analysis
